Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
Meeting ReportPoster - PhysicianPharm

Emerging role of FDG-PET/CT for global assessment of bone marrow involvement in chronic lymphocytic leukemia

Raheleh Taghvaei, Reza Sirous, Amir Amanullah, Thomas Werner, Mona-Elisabeth Revheim, Poul Flemming Hoilund-Carlsen and Abass Alavi
Journal of Nuclear Medicine May 2021, 62 (supplement 1) 1690;
Raheleh Taghvaei
1Department of Radiology Hospital of the University of Pennsylvania Philadelphia PA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Reza Sirous
2Harlem Hospital Center Program Bronx NY United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amir Amanullah
3Hospital of the University of Pennsylvania Philadelphia PA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Werner
3Hospital of the University of Pennsylvania Philadelphia PA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mona-Elisabeth Revheim
4Oslo University Hospital Oslo Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Poul Flemming Hoilund-Carlsen
5Odense University Hospital Odense C, Funen Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Abass Alavi
3Hospital of the University of Pennsylvania Philadelphia PA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

1690

Objectives: Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in the United States. The CLL cells mostly proliferate in the secondary lymphoid tissues, but can also undergo mitosis in the proliferation centers in the bone marrow, which are named “pseudofollicles” areas. PET imaging has been used to detect Richter syndrome, a disease which involves the transformation of CLL to a more aggressive lymphoma. This application relies on measurement of tracer uptake in focal lesions. However, the global assessment of bone marrow involvement has yet to be investigated. This study evaluates a global quantification method to assess bone marrow involvement using FDG-PET/CT based on CT segmentation in CLL patients.

Methods: Eighteen patients with CLL (15 Males, 3 Females, aged 41-80 years) were enrolled in a retrospective study. PET/CT scans were performed 60 minutes after intravenous injection of 18F-fluorodeoxyglucose (FDG) at the Hospital of the University of Pennsylvania. The patients were matched to 17 healthy controls by sex and age (± 5 year) from the CAMONA study. An iterative thresholding algorithm (OsiriX, Pixmeo SARL, Bernex, Switzerland) was applied to quantify FDG uptake limited to the skeleton, with lower and upper boundaries set at 150-1500 Hounsfield units on the fused PET/CT scans. The global mean standardized uptake value (global SUVmean) was reported for each patient and control subject,. FDG uptake was compared between healthy controls and CLL patients. Statistical analysis was performed using SPSS 24. Results: The average (± SD) of the global bone SUVmean in CLL patients was significantly higher than in healthy control subjects: 1.09 ± 0.13 vs. 0.82 ± 0.21, p = 0.014. Conclusion: The results of this study show that global SUVmean can be used as an indicator for bone marrow metabolic activity in patients with CLL. The increased bone marrow activity may reflect an increased proliferation of CLL cells. Further studies are needed to investigate the correlation of global SUVmean with disease burden and response to treatment.

Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 62, Issue supplement 1
May 1, 2021
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Emerging role of FDG-PET/CT for global assessment of bone marrow involvement in chronic lymphocytic leukemia
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Emerging role of FDG-PET/CT for global assessment of bone marrow involvement in chronic lymphocytic leukemia
Raheleh Taghvaei, Reza Sirous, Amir Amanullah, Thomas Werner, Mona-Elisabeth Revheim, Poul Flemming Hoilund-Carlsen, Abass Alavi
Journal of Nuclear Medicine May 2021, 62 (supplement 1) 1690;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Emerging role of FDG-PET/CT for global assessment of bone marrow involvement in chronic lymphocytic leukemia
Raheleh Taghvaei, Reza Sirous, Amir Amanullah, Thomas Werner, Mona-Elisabeth Revheim, Poul Flemming Hoilund-Carlsen, Abass Alavi
Journal of Nuclear Medicine May 2021, 62 (supplement 1) 1690;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Poster - PhysicianPharm

  • Preliminary result of Texture Analysis on prediction of overall outcome of neuroendocrine tumors based on pre-therapy heterogeneity of somatostatin receptors on 68Ga Dotatate PET/CT scans.
  • Application of 18F-FDG PET/CT in early detection of therapy-associated cardiotoxicity in patients with lymphoma.
  • Value of interim FDG PET/CT for monitoring response to therapy and predicting prognosis in Hodgkin’s lymphoma treated with ABVD chemotherapy
Show more Poster - PhysicianPharm

Leukemia/Lymphoma/Myeloma

  • A clinical study of baseline PET/CT parameters in the prediction of refractory/ relapsed diffuse large B cell lymphoma of advanced stage patients
  • Value of interim FDG PET/CT for monitoring response to therapy and predicting prognosis in Hodgkin’s lymphoma treated with ABVD chemotherapy
  • Low brain FDG uptake in lymphoma patients represents preferential use of high blood lactate released by total lesion glycolysis.
Show more Leukemia/Lymphoma/Myeloma

Similar Articles

SNMMI

© 2022 Journal of Nuclear Medicine

Powered by HighWire